2024-09-16 - Analysis Report
## PFE Stock Analysis

**Company Overview:** Pfizer Inc. (PFE) is a global pharmaceutical company that develops and markets a wide range of medicines and vaccines.

**Performance Analysis:**

1. **Performance Compared to S&P 500:**
    * **Cumulative Return:** PFE's cumulative return is -26.24%, significantly lower than the S&P 500's 88.73%. 
    * **Relative Performance:** The stock is currently lagging behind the S&P 500 by -114.97%, placing it at the 2.21% mark on the historical performance range.
    
2. **Recent Price Action:**
    * **Closing Price:** $29.27
    * **Moving Averages:** 
        * 5-day moving average: $29.45
        * 20-day moving average: $28.90
        * 60-day moving average: $28.98
    * **Interpretation:** The stock is currently trading slightly below its 5-day moving average, suggesting some short-term weakness. However, the 20-day and 60-day moving averages are relatively close, indicating stability in the longer term.

3. **Technical Indicators:**
    * **RSI:** 55.52 (Neutral)
    * **PPO:** 0.32 (Slight Bullish)
    * **Delta_Previous_Relative_Divergence:** -1.16 (Short-term Downward Trend)
    * **Expected Return:** 0.0% (5-year maximum expected return)
    * **Interpretation:** The RSI indicates a neutral market sentiment, while the PPO suggests a slight bullish bias. However, the negative delta in the relative divergence points towards a potential short-term downward trend. The expected return of 0.0% suggests limited potential for significant gains in the near future.

4. **Recent Earnings and Outlook:**
    * **Last Earnings Report (2024-07-30):** EPS of $0.60 exceeded the estimated EPS of $0.458.
    * **Trend:** Pfizer has consistently exceeded earnings expectations in the past, indicating strong profitability.
    * **Outlook:** The company's future outlook appears promising due to its robust pipeline of new drugs and vaccines.  

**Overall Analysis:**

* PFE is currently lagging behind the S&P 500, with a significant underperformance compared to the broader market.
* The stock exhibits a slight bullish bias, with the PPO suggesting potential for upward movement. However, the negative divergence in the relative indicator suggests a potential short-term decline. 
* The recent earnings performance has been strong, with the company consistently exceeding expectations. This indicates a robust business model and promising future growth prospects.
* While the expected return is currently low, the company's strong financial performance and future pipeline of new drugs and vaccines could drive future growth.

**Recommendation:**

Investors with a long-term horizon might consider PFE as a potential addition to their portfolio, as the company's strong earnings record and future prospects suggest potential for growth. However, the current negative divergence in the relative indicator warrants caution in the short term. 
